H.C. Wainwright raised the firm’s price target on ChromaDex (CDXC) to $8 from $6 and keeps a Buy rating on the shares post the Q3 report. The company reported slight sales outperformance and solid earnings beat with “multiple potential tailwinds,” the analyst tells investors in a research note.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter